Researchers conducted the study, which involved 1,090 Pfizer vaccine recipients, to investigate whether people with prior COVID-19 infection have naturally acquired immunity that could be sufficiently enhanced by a single mRNA vaccine dose compared to receiving two doses.
The study also revealed post-vaccination symptoms were more prominent among those with prior infection after the first dose and were similar among both groups after the second dose.
More articles on pharmacy:
FDA downplayed safety risks at Merck plant producing J&J COVID-19 vaccines, whistleblower says
White House knew 2 weeks ago that plant producing J&J vaccine had problems, Politico says
Walgreens reports strong Q2 results thanks to COVID-19 vaccine rollout
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
